AstraZeneca to pay $198m to patients over diabetes claimsBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4422 (Published 13 August 2010) Cite this as: BMJ 2010;341:c4422
- Janice Hopkins Tanne
- 1New York
The US drug company AstraZeneca announced this month that it will pay out $198m (£127m; €155m) to 17 500 patients, most of whom claimed that the antipsychotic drug quetiapine fumarate (Seroquel) had caused them to develop diabetes.
The company has reached agreements in principle with attorneys representing patients, but the agreements have not yet been finalised. The specific terms of the agreement, which resulted from court ordered mediation, are confidential.
The company spokesperson Tony Jewell told the BMJ, “Plaintiffs generally …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial